Fig. 3From: The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmissionSame model result as in Fig. 2, but with tOPV and bOPV take rates calculated directly from cumulative 2-dose seroconversion estimates reported by Sutter et al. (2010)[27] (see Table 1). a Population immunity to serotype 1 poliovirus transmission. b Population immunity to serotype 2 poliovirus transmission. c Population immunity to serotype 3 poliovirus transmissionBack to article page